Background: The Asia-Pacific consensus guidelines for the management of chronic hepatitis B state that the principal indicators for starting therapy are increased HBV DNA levels (≥20,000 IU/ml for hepatitis B e antigen [HBeAg]-positive status and >2,000 IU/ml for HBeAgnegative status) and alanine aminotransferase (ALT) levels >2× the upper limit of normal. We aimed to determine whether clinicians in the Asia-Pacific region are treating patients with chronic hepatitis B according to the Asia-Pacific consensus statement on the management of chronic hepatitis B. Methods: An online survey of chronic hepatitis B treatment practices was prepared, consisting of 14 questions grouped into seven categories: patient statistics, treatment statistics, treatment decision, first-choice treatment, treatment duration, future directions and patient preference.
Introduction
approximately 20% of HBeAg-negative patients receiving combination therapy [4] [5] [6] [7] . In these clinical trials, treatment with PEG-IFN-α2a or PEG-IFNα2b plus lamivudine was more effective than treatment with lamivudine monotherapy [5, 7] ; however, the addition of lamivudine to PEG-IFN appeared to confer no additional benefit compared with PEG-IFN monotherapy [5, 7, 8] . Oral antiviral medications, such as lamivudine, adefovir dipivoxil [9] [10] [11] , entecavir [12] , telbivudine [13, 14] and, more recently, tenofovir [15, 16] are also approved for the treatment of chronic hepatitis B and provide several different treatment options for these patients. As the number of therapeutic alternatives increases, regular updates of treatment guidelines are necessary to keep physicians aware of evolving clinical practice.
The Asia-Pacific consensus guidelines for the management of chronic hepatitis B state that the principal indicators for starting antiviral therapy are increased HBV DNA levels (≥20,000 IU/ml for HBeAg-positive status and >2,000 IU/ml for HBeAg-negative status) and alanine aminotransferase (ALT) levels >2× the upper limit of normal (ULN) [17, 18] . Although patients with persistently normal ALT or minimally increased ALT levels generally should not be treated, those with advanced fibrosis or cirrhosis might be considered for treatment [18] . In addition, some authors have suggested that an ALT level exceeding 2× the ULN range is not appropriate as the standard indication for treatment [19] . With the introduction of more potent nucleoside/nucleotide analogues, such as entecavir and tenofovir, it has been proposed that the ALT threshold for beginning antiviral therapy should be lowered, and that patients with ALT levels between 0.5× and 2×ULN should be treated [19] . Recommended first-line treatment options are conventional IFN-α, PEG-IFN-α2a, lamivudine, telbivudine, entecavir and adefovir dipivoxil [18] ; however, there might be a reluctance to use IFN therapy because of the concern about adverse effects associated with this medication [20] . In addition, a strong body of evidence supports the use of PEG-IFN-α2b in the treatment of HBeAg-positive patients with chronic hepatitis B, with data from the HBV 99-01 study indicating that the addition of lamivudine to PEG-IFN-α2b provides no incremental benefit compared with PEG-IFNα2b monotherapy [6, [21] [22] [23] . Other studies support the use of PEG-IFN-α2b for the treatment of patients with chronic hepatitis B; one such study is that by Chan et al. [4] , who reported sustained responses in 36% of patients receiving PEG-IFN-α2b plus lamivudine and 14% of those receiving lamivudine monotherapy (P=0.011). Collectively, these data have resulted in the approval of PEG-IFN-α2b for the treatment of chronic hepatitis B in many Asian countries [18] , including China, India, Bangladesh, Cambodia, Indonesia, Malaysia, the Philippines, Thailand and Vietnam. To date, registration studies for the treatment of HBV with PEG-IFN-α2b have not been conducted in the US or in Europe. The Asia-Pacific consensus guidelines committee is awaiting these registration trials before officially updating the treatment guidelines for chronic hepatitis B in the Asia-Pacific region.
It is recommended that IFN-α-based therapy be administered for a fixed duration of treatment. In HBeAg-positive patients, conventional IFN therapy should be given for 4-6 months and PEG-IFN-α2a should be given for at least 6 months. In HBeAg-negative patients, a 12-month treatment duration is recommended for both agents [18] . For oral antiviral therapies, recommendations regarding duration of therapy are on the basis of serum and virological end points. In HBeAg-positive patients, treatment should be stopped when HBeAg seroconversion with undetectable HBV DNA is documented on at least two occasions, separated by an interval of 6 months. In HBeAg-negative patients, oral antiviral therapy might be discontinued if HBV DNA is undetectable on at least three separate occasions 6 months apart.
The objective of the present study was to survey the practices used in the management of chronic hepatitis B by clinicians in the Asia-Pacific region in order to determine whether practitioners are adhering to the Asia-Pacific consensus statement on the management of chronic hepatitis B [17, 18] .
Methods
An online survey of treatment practices in the field of hepatitis B in the Asia-Pacific region was conducted. The survey consisted of 14 questions grouped into seven categories: patient statistics, treatment statistics, treatment decision, first-choice treatment, treatment duration, future directions and patient preference. The survey also included five case studies. For each case, clinicians were asked whether they would consider initiating therapy. All known physicians with an active interest in chronic hepatitis B in the Asia-Pacific region received a personal invitation to participate in the survey.
The survey was conducted between May 2007 and July 2007 with participants selected from a registry of gastrointestinal specialists. Initially, invitations to participate were written in English and distributed electronically. Many of the invitees, however, particularly those from China, experienced language difficulties with the initial survey; therefore, a Chinese translation of the survey was resent to certain participants. To provide an incentive to participate, all completed entries were also entered into a draw to win a hepatology text book (English-speaking participants) or a book on presentation skills (Chinesespeaking participants).
Ethical approval for the conduct of this study was not sought because no individual patient data were requested from the participants.
Results
In total, 384 physicians from 12 cities or countries in the Asia-Pacific region (Australia, China, Hong Kong SAR, India, Indonesia, Malaysia, Pakistan, the Philippines, Singapore, South Korea, Taiwan and Thailand) were invited to participate in the survey (Table 1) . Replies were received from 124 (32.3%) respondents and were included in the final analysis. Most participants (36, 29%) were from China, with all other countries contributing <10% each of the total respondent population.
Patient profiles
The survey revealed that respondents reported seeing an average of 19 HBeAg-positive and 20 HBeAg-negative patients with chronic hepatitis B in clinical practice per week, with a mean of four new HBeAg-positive and five new HBeAg-negative patients. The survey also revealed that in the clinic of each respondent, an average of 60 HBeAg-positive and 50 HBeAg-negative patients had received treatment for chronic hepatitis B during the past 12 months. On average, 10 HBeAg-positive and 7 HBeAg-negative patients were reported to have initiated treatment during the previous 12 months.
Initiation of treatment
HBV DNA levels were considered the most important factor in deciding whether to treat patients infected with HBV; 59.6% of respondents indicated that HBV DNA was the first or second most important factor when deciding whether to initiate therapy (Figure 1 ). ALT level and liver histology stage were reported by 45% and 33% of respondents, respectively, to be the first or second most important consideration when deciding when to initiate therapy. Notably, respondents did not report age or HBeAg status as important factors when considering initiation of treatment for HBV infection.
Survey respondents were asked to evaluate five case studies and to decide whether they would initiate treatment in each patient (Figure 2 ). The cases differed with respect to ALT levels, HBV DNA levels, HBeAg status and age. Of the five patient cases presented, four had normal ALT levels. Most respondents would not recommend treatment in young (≤30 years of age), HBeAg-positive (64.5%) or HBeAg-negative (54.8%) patients with ALT levels within the normal range. By contrast, if ALT levels were high (120 IU/ml), most (89.5%) respondents would recommend treatment. In older patients (≥45 years) with normal ALT levels, treatment strategies appeared less well defined, and many respondents indicated they were uncertain whether they would initiate treatment in HBeAg-positive (46.0%) or HBeAg-negative (54.1%) patients. Opinions were divided among the remaining respondents about whether to treat these patients ( Figure 2 ).
Choice of therapy
Respondents reported that 62% of patients were receiving oral antiviral therapy, 15% were receiving IFN therapy and 5% were receiving two oral antiviral agents. None of the respondents reported the use of thymosin or an oral antiviral in combination with IFN. Respondents reported that 80% of patients undergoing therapy preferred oral antiviral treatment and 20% preferred IFN or PEG-IFN treatment.
Survey participants were asked to choose the reasons for their preferred treatment of choice from a list ( Figure 3 ). The most common reasons for selecting an oral antiviral therapy were effectiveness (34.7%), sustained viral suppression (25.8%) and safety (12.9%). Few participants reported that they use oral antiviral therapy because of guideline recommendations (7.9%) or because resistance can be easily managed (1.6%). The most common reasons for selecting IFN therapy were fixed duration of treatment (33.1%), effectiveness (31%) and lack of resistance (11.3%). Few respondents reported that IFN was their treatment of choice because of cost considerations (2.1%) or safety (1.6%).
When to stop treatment
Survey participants were asked to select criteria they use for stopping hepatitis B therapy in HBeAg-positive and HBeAg-negative patients (Figure 4 ).
Oral antiviral medications
The most frequently cited reasons for stopping therapy in HBeAg-positive patients receiving oral antiviral therapy were that a treatment period of at least 6 months after seroconversion had elapsed (58.1%) and a treatment period at least 6 months after undetectable HBV DNA had elapsed (16.1%). Similarly, in HBeAg-negative patients, the most frequently cited reasons for stopping oral therapy were that a period of at least 12 months (42.7%) or of 6 months (15.3%) had elapsed since HBV DNA became undetectable and that the patient had completed >5 years of therapy (12.1%). Absolute duration of therapy was not considered as an important factor in defining treatment duration for chronic hepatitis B patients receiving oral antiviral therapy.
Interferon-α-based medications
In contrast to the use of oral antiviral medications, a 12-month fixed duration of therapy was the most frequent reason for stopping IFN therapy in HBeAg-positive (36.3%) and HBeAg-negative (47.6%) patients. In HBeAg-positive patients, 6 months of therapy (16.9%) or a period of at least 6 months after HBeAg seroconversion 14.5 Respondents, % The breakdown of responses to the question 'Would you treat the following male patients, assuming that each of these labs were repeated 3 months later and showed similar results?' is shown. Of the responses received, 1.6% were blank. ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen.
(13.7%) were also frequently cited reasons for stopping IFN therapy; whereas, in HBeAg-negative patients, a period of at least 6 months after undetectable HBV DNA (15.3%) was also frequently cited as a reason for stopping IFN therapy.
Future treatment of chronic hepatitis B
Overall, 47.6% of survey respondents felt that improvements in treatment outcomes would most likely be achieved by combining PEG-IFN-α and oral antiviral therapy. Fewer respondents reported that combining at least two antiviral agents (19.4%) or using a higher PEG-IFN-α dose or longer treatment duration (12.9%) represented effective strategies to improve chronic hepatitis B treatment outcomes. Survey participants were asked to select, from a series of alternatives, how treatment of chronic hepatitis B would evolve in the next 3 years. The two most commonly selected practices were 'confirmation of resistance mutations in patients with breakthrough infection' (75% of respondents) and 'screening for resistance mutations during treatment' (71.8% of respondents). Fewer respondents considered genotyping before treatment (56.5%), resistance mutation testing before treatment (50.8%) and quantification of hepatic covalently closed circular DNA (38.7%) 
Discussion
On the basis of the results of this survey, several observations can be made with regard to treatment of chronic hepatitis B in the Asia-Pacific region. Most clinicians in the region consider HBV DNA levels to be more important than ALT levels when considering treatment initiation for patients with chronic hepatitis B infection and oral antiviral treatment is preferred over IFN therapy. With 80% of patients preferring oral antiviral therapy, it appears that patient preference might be a major factor in the widespread use of oral antivirals rather than IFN-based therapy. Current guidelines are universal in their recommendation that treatment should not be initiated in patients with ALT levels <2×ULN, except in patients with advanced fibrosis or cirrhosis [17, 18, 24] . It is therefore noteworthy that approximately 50% of all respondents answered 'maybe' when asked about initiating therapy in two patients with normal ALT levels. This response implies that respondents would seek further clinical information before making a definitive decision and it might be speculated that because both patients were older (aged 45 and 55 years), physicians might seek further clarification regarding stage of liver disease (which might be more advanced in older patients). Indeed, liver biopsy is considered a useful element of pretreatment management among patients who do not clearly meet the criteria for starting therapy [25] . Guidelines from the American Association for Study of Liver Disease (AASLD; 2007) [24] recommend that liver histology be considered in patients older than 40 years who have fluctuating or minimally increasing ALT levels. Similarly, recent guidelines from the Asia-Pacific Association for Study of the Liver (APASL) also state that histological assessment of a liver biopsy specimen is recommended in patients with high to normal ALT levels who are older than 40 years. Interestingly, this guidance is absent from the 2005 APASL guidelines (which were current for the Asia-Pacific region at the time of the survey) and leads us to speculate that prescribing practices in Asia-Pacific at the time of the survey were at least partially influenced by the more up-to-date AASLD practice recommendations.
It is also apparent that studies are required to evaluate the use of more potent antiviral therapies, such as entecavir, in the treatment of patients with chronic hepatitis B and relatively low (1-2×ULN) ALT levels. This, in turn, raises questions about the appropriate definition of the normal ALT level and whether it should be considered lower than the currently accepted 40-45 IU/ml. Nevertheless, although lack of information regarding stage of fibrosis might provide some insight into why many physicians were unsure about treating two patients with normal ALT levels, it does not explain why 29.8% of respondents felt that HBV DNA levels were the most important factor in deciding whether to initiate therapy, or that 25% of respondents felt liver histology was the most important consideration. However, we also acknowledge that ranking diagnostic criteria according to importance might be somewhat misleading and not entirely consistent with the manner in which these criteria are used in routine clinical practice. Clinicians invariably use a composite of several diagnostic criteria in selecting an appropriate treatment; thus, framing the question to identify one particular factor as 'most important' is not consistent with the manner in which hepatologists treat patients with chronic hepatitis B.
Current treatment recommendations for the AsiaPacific region state no preference for first-line treatment among the approved therapies (conventional IFN, PEG-IFN, entecavir, adefovir, telbivudine, lamivudine or thymosin); however, this is not reflected in the survey responses. In total, 62% of patients in the care of respondents were receiving oral antiviral therapy, but only 15% were receiving IFN therapy. In addition, 80% of patients themselves indicated a preference for oral antiviral treatment. Preference for antiviral therapy was based on effectiveness, safety and maintained viral suppression; however, these beliefs are not entirely consistent with clinical trial data. Studies indicate that sustained biochemical and virological treatment outcomes are better in patients receiving PEG-IFN-α2a than lamivudine, albeit at the cost of a less favourable tolerability profile and poorer viral suppression while on treatment [5, 7] . Although combination therapy with PEG-IFN-α plus lamivudine appears to suppress HBV DNA levels more effectively than lamivudine monotherapy [4, 7] , several studies suggest that PEG-IFN-α monotherapy might achieve therapeutic outcomes similar to those of PEG-IFN-α plus lamivudine combination therapy [6, 7, 26, 27] . Indeed, in the investigator-initiated HBV 99-01 study, HBeAg loss was reported in 35% of HBeAg-positive patients receiving PEG-IFN-α2b plus lamivudine and in 36% of patients receiving PEG-IFN-α2b alone [6] . Suppression of HBV DNA levels during treatment was greater in the combination therapy arm and, at the end of treatment, 74% of patients receiving PEG-IFN-α2b plus lamivudine and 40% of those receiving PEG-IFN-α2b alone had HBV DNA levels <200,000 copies/ml (P<0.0001). However, relapse during post-treatment follow-up was greater in the combination therapy arm. At the end of follow-up, 32% of patients receiving PEG-IFN-α2b plus lamivudine and 27% of those receiving PEG-IFNα2b monotherapy had HBV DNA levels <200,000 copies/ml [6] . Furthermore, in this study, treatment with PEG-IFN-α2b was associated with improved liver necroinflammation and fibrosis, particularly among responders [21] , and with a favourable safety profile consistent with the well-described adverse events associated with IFN-based therapy [22] .
Among the reasons for selecting IFN-based therapy, 'more effective' was reported by 31% of respondents; thus, effectiveness was cited as a primary reason among respondents preferring oral antiviral therapy and among those preferring IFN-based therapy. This seems contradictory but might be related to different treatment goals: oral antiviral therapy offers more sustained and effective suppression of HBV DNA than PEG-IFN-α therapy while patients are on treatment, whereas PEG-IFN-α offers a greater likelihood of sustained response than oral antiviral therapy once treatment is stopped [4, 5, 7] . For example, in one study, 36% of patients receiving PEG-IFN-α2b plus lamivudine but only 14% of those receiving lamivudine monotherapy had sustained virological response (P=0.011), defined as loss of HBeAg, detection of HBeAg antibody and HBV DNA levels <500,000 copies/ml at 24 weeks after the end of treatment [4] . Similarly, HBeAg loss at 24 weeks after completion of therapy is reported in 34% of patients receiving PEG-IFN-α2a and 21% of those receiving lamivudine monotherapy (P<0.001). Virological response (HBV DNA<400 copies/ml) occurred in 14% and 5% of patients, respectively [5] .
The fixed duration of treatment associated with IFNbased therapy is also an important consideration for many respondents when selecting this therapy. It has been reported that PEG-IFN therapy should be considered primarily for patients younger than 25 years with recently acquired infection because of the defined duration of therapy and the potential for durable response [25] . The appropriate time to stop therapy with oral antiviral agents in HBeAg-positive patients with very low HBV DNA levels is regarded as 6-12 months after seroconversion. In HBeAg-negative patients, the best time is unclear because of the very high likelihood of relapse, even among patients who experience prolonged periods of undetectable HBV DNA [25] . A road map for the management of chronic hepatitis B has recently been proposed based on week 24 HBV DNA levels with the objective of minimizing long-term resistance and improving long-term efficacy. This approach advocates the addition of a second oral antiviral medication or the switch to a more potent antiviral drug in patients with detectable HBV DNA after 24 weeks of therapy [3] . Interestingly, almost half of all respondents in the present survey reported that combining PEG-IFN with a more potent oral antiviral therapy was the strategy most likely to result in improved response rates. By contrast, <20% of respondents reported that combining two or more antiviral agents was an optimal strategy. In addition, screening for resistance mutations during treatment and after breakthrough infection is considered the practice most likely to be adopted in routine clinical practice in the next 3 years.
A survey of treatment practices for HBV and HIV coinfection in the US has reported similar observations [28] . This survey also indicated some disparity with regard to the factors used for initiating therapy. In total, 42% of respondents indicated they would initiate treatment in patients with increased aspartate transaminase (AST) and ALT levels and an HBV DNA level >10 5 copies/ml, whereas 49% of respondents recommended therapy for all patients with HBV DNA level >10 5 copies/ml regardless of ALT and AST levels. This survey also reported a predominance of respondents favouring the use of oral antiviral therapy. Only 24% of patients not receiving antiretroviral therapy and 11% of those receiving antiretroviral therapy were receiving IFNbased treatment for their HBV infection. The majority of the other patients favoured the use of oral antiviral drugs [28] . Finally with regard to cessation of therapy for chronic hepatitis B, 46% of respondents recommended continuing therapy indefinitely for patients not receiving antiretroviral therapy. In addition, 20% of respondents recommended discontinuing therapy in patients with a persistent loss of HBsAg, whereas 34% recommended discontinuing therapy in patients with seroconversion from HBeAg-positive to HBeAgantibody-positive. Clearly, comparison of the results from our study and those reported by Gaglio et al. [28] are confounded by the assessment of HBV-HIV-coinfected patients in the latter study. In this patient cohort, the use of antiretroviral medications and the desire to use medications active against both viruses (including lamivudine plus tenofovir or emtricitabine plus tenofovir) will affect physician choice of medication. However, in other respects, namely disregard of ALT levels when considering initiation of therapy for chronic hepatitis B, observations among physicians in the US correlate closely with observations among physicians in the Asia-Pacific region [28] .
This study has several limitations. First, the relatively low response rate (32%) and final number of respondents (n=124) might limit the interpretation of the results. Estimates of the number of hepatologists practicing throughout the Asia-Pacific region are not available; however, it can be reasonably expected that throughout this region, many thousands of physicians treat patients with chronic hepatitis B on a regular basis. Thus, it cannot be concluded that data from the present survey, which included a limited number of hepatologists, is representative of the Asia-Pacific region. In addition, the over-representation of respondents from China (29%) means that the overall results are heavily influenced by clinical practice in this country and the other countries are almost certainly inadequately represented. Second, given the absence of a formal assessment of the survey instrument, it is unknown whether the structure or wording of the survey might contain an inherent source of bias. In particular, our survey did not account for the fact that physicians might use different therapies in different patient groups. Current guidelines indicate that disease severity, history of flares, hepatic function, rapidity of drug action, resistance profile, adverse effects, cost and patient preference should be taken into account when selecting the most appropriate treatment strategy [18] . There were also no control measures taken to ensure that the survey instrument was accurately translated into Chinese language. The instrument was not back-translated to check for accuracy and thus we cannot be certain that the interpretation and meaning of the survey questions were preserved in the Chinese language version. Other important factors not accounted for in this survey might include equal access to all medications in all regions and any implications of their relative costs. Our survey also assumed that all therapies were available in all countries; however, this is generally not the case. For example, telbivudine was approved for treatment of chronic hepatitis B in China in early 2007, only a matter of weeks before our survey was released. It is unclear whether the impending availability of this agent would change prescribing practices in China during the period of the survey. Finally, our survey was conducted before the publication of updated chronic hepatitis B treatment guidelines for the Asia-Pacific region [18] ; thus, with the recent approval of new agents and their inclusion in the revised guidelines, it is unclear how closely these observations reflect current clinical practice. However, it is our belief that many of the observations arising from this study, such as those regarding medication preferences and decisions to treat, remain valid and provide valuable insight into the influence of treatment guidelines in defining day-today clinical practice.
In conclusion, data from this survey suggest that clinicians from the Asia-Pacific region use criteria beyond those advocated in treatment guidelines when deciding whether to initiate treatment in HBV-infected patients. Treatment of chronic hepatitis B is rapidly evolving and new treatment options are continually being added to the therapeutic armamentarium. Although limited by small sample size and certain methodological issues, the results from the current survey suggest certain inconsistencies exist between guidelines and clinical practice with regard to the relative importance of virological and biochemical markers when initiating treatment. These observations also confirm common perceptions, such as the benefit associated with fixed-term treatment duration with IFN-based therapy and the favourable tolerability profile of the oral antiviral agents. Further studies that include the use of a larger sample that is more representative of the Asia-Pacific region and which uses an appropriately validated questionnaire is required to understand whether physicians will align their clinical practice more closely with recently updated guidelines.
